Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Early On-treatment Transcriptional Profiling as Predictor of Response in Early-stage HER2-positive Breast Cancer (BiOnHER)

NCT05912062 is registered in ClinicalTrials.gov with Institut Català d'Oncologia as lead sponsor.

NCT NCT05912062
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05912062 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Early On-treatment Transcriptional Profiling as Predictor of Response in Early-stage HER2-positive Breast Cancer (BiOnHER)
Lead sponsor
Institut Català d'Oncologia
Phase
Observational
Overall status
Unknown status
Start date
March 22, 2021
Completion date
December 1, 2024
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, her2-positive breast cancer, neoplasms